Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK2 | O00142 | 3/20 | 0.41 |
| ▸ | TK1 | P04183 | 2/20 | 0.40 |
| ▸ | TOP2A | P11388 | 4/20 | 0.38 |
| ▸ | TYMP | P19971 | 3/20 | 0.37 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL313035 | 1.00 | TK2 (0.41) | TK2TK1TOP2ATYMPRNASE1 | |
| SCHEMBL1738250 | 0.93 | TK2 (0.42) | TK2TK1TOP2ATYMP | |
| SCHEMBL7065019 | 0.92 | TK2 (0.42) | TK2TK1TOP2ATYMP | |
| SCHEMBL7065021 | 0.92 | TK2 (0.42) | TK2TK1TOP2ATYMP | |
| SCHEMBL7901416 | 0.91 | DNPH1 (0.38) | TK2 | |
| SCHEMBL7901418 | 0.91 | DNPH1 (0.38) | TK2 | |
| SCHEMBL261288 | 0.91 | TK2 (0.47) | TK2TK1TOP2ATYMPRNASE1 | |
| SCHEMBL19812217 | 0.91 | TK2 (0.47) | TK2TK1TOP2ATYMPRNASE1 | |
| SCHEMBL261289 | 0.91 | TK2 (0.47) | TK2TK1TOP2ATYMPRNASE1 | |
| SCHEMBL7247156 | 0.91 | TK2 (0.41) | TK2TK1TOP2ATYMP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1269 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11859186-B2 | Antisense oligonucleotides useful in treatment of Pompe disease | ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM (NL) | 2024-01-02 | — | — | US | disclosed |
| US-20220288100-A1 | 2'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS | IONIS PHARMACEUTICALS, INC. (US) | 2022-09-15 | — | — | US | disclosed |
| EP-4039807-A1 | ANTISENSE OLIGONUCLEOTIDES USEFUL IN TREATMENT OF POMPE DISEASE | Erasmus University Rotterdam Medical Center (NL) | 2022-08-10 | — | — | EP | disclosed |
| US-20220162603-A1 | COMPOSITIONS COMPRISING ALTERNATING 2'-MODIFIED NUCLEOSIDES FOR USE IN GENE MODULATION | IONIS PHARMACEUTICALS, INC. (US) | 2022-05-26 | — | — | US | disclosed |
| EP-3155100-B1 | ANTISENSE OLIGONUCLEOTIDES USEFUL IN TREATMENT OF POMPE DISEASE | UNIV ERASMUS MED CT ROTTERDAM (NL) | 2021-12-22 | — | — | EP | disclosed |
| US-20210322526-A1 | ENZYMATIC REPLACEMENT THERAPY AND ANTISENSE THERAPY FOR POMPE DISEASE | UNIV ERASMUS MED CT ROTTERDAM (NL) | 2021-10-21 | — | — | US | disclosed |
| US-11078485-B2 | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation | IONIS PHARMACEUTICALS, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-20210139913-A1 | ANTISENSE OLIGONUCLEOTIDES USEFUL IN TREATMENT OF POMPE DISEASE | UNIV ERASMUS MED CT ROTTERDAM (NL) | 2021-05-13 | — | — | US | disclosed |
| US-10993995-B2 | Enzymatic replacement therapy and antisense therapy for pompe disease | ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM (NL) | 2021-05-04 | — | — | US | disclosed |
| US-10829764-B2 | Antisense oligonucleotides useful in treatment of Pompe disease | ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM (NL) | 2020-11-10 | — | — | US | disclosed |
| US-5981732-A | ANTISENSE OLIGONUCLEOTIDES WHICH TARGET THE EXPRESSION OF A G PROTEIN | ISIS PHARMACEUTICALS INC. (US) | 1999-11-09 | — | — | US | disclosed |
| US-5977341-A | Antisense modulation of inhibitor-kappa B kinase-beta expression | ISIS PHARMACEUTICALS INC. (US) | 1999-11-02 | — | — | US | disclosed |
| US-5962673-A | ANTISENSE AGENT 8 TO 30 NUCLEOBASES IN LENGTH; FOR DIAGNOSIS AND TREATMENT OF ASTHMA, MYASTHENIA GRAVIS, GRAVES' DISEASE, ALLOGRAFT REJECTION, PSORIASIS AND OTHERS; ANTITUMOR/ ANTIPROLIFERATIVE/ANTIDIABETIC/ANTIARTHRITIC AGENTS | ISIS PHARMACEUTICALS INC. (US) | 1999-10-05 | — | — | US | disclosed |
| US-5958771-A | OLIGONUCLEOTIDE FROM 8 TO 30 NUCLEOTIDES IN LENGTH; FOR DIAGNOSIS AND THERAPY; ANTITUMOR/ANTIINFLAMMATORY AGENTS | ISIS PHARMACEUTICALS, INC. (US) | 1999-09-28 | — | — | US | disclosed |
| US-5959097-A | OLIGONUCLEOTIDE OF 8 TO 30 NUCLEOTIDES WHICH SUPPRESSES EXPRESSION OF SIGNAL TRANSDUCTION KINASE; FOR TREATMENT OF INFECTIONS; ANTIINFLAMMATORY/ANTITUMOR AGENTS | ISIS PHARMACEUTICALS, INC. (US) | 1999-09-28 | — | — | US | disclosed |
| US-5958773-A | ANTISENSE COMPOUND 8 TO 30 NUCLEOTIDES IN LENGTH TARGETED TO A NUCLEIC ACID ENCODING HUMAN AKT-1, OF THE SERINE/THREONINE KINASE FAMILY INVOLVED IN SIGNALLING PATHWAYS; INHIBITING EXPRESSION OF AKT-1 WITH THE ANTISENSE COMPOUND | ISIS PHARMACEUTICALS INC. (US) | 1999-09-28 | — | — | US | disclosed |
| US-5958772-A | TARGETS TO NUCLEIC ACID MOLECULE ENCODING HUMAN CELLULAR INHIBITORS OF APOTOPSIS-1 | ISIS PHARMACEUTICALS INC. (US) | 1999-09-28 | — | — | US | disclosed |
| US-5951455-A | OLIGONUCLEOTIDES, TARGETED TO NUCLEIC ACIDS WITH MODULATION AND EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 1999-09-14 | — | — | US | disclosed |
| US-5948680-A | ANTISENSE OLIGONUCLEOTIDE TARGETED TO NUCLEIC ACIDS ENCODING ELK-1; ANTIPROLIFERATIVE AGENTS | ISIS PHARMACEUTICALS INC. (US) | 1999-09-07 | — | — | US | disclosed |
| EP-0786445-A1 | DIFLUOROXYMETHANE DERIVATIVE AND LIQUID CRYSTAL COMPOSITION | CHISSO CORPORATION (JP) | 1997-07-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11078485-B2 | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation | NSUN2, RNMT, NSUN3 | TK2 743/4885TK1 1028/4885TOP2A 1611/4885 |
| US-20210322526-A1 | ENZYMATIC REPLACEMENT THERAPY AND ANTISENSE THERAPY FOR POMPE DISEASE | GAA, GBA3, GBA1 | TK2 1877/4885TK1 443/4885TOP2A 4164/4885 |
| US-20220162603-A1 | COMPOSITIONS COMPRISING ALTERNATING 2'-MODIFIED NUCLEOSIDES FOR USE IN GENE MODULATION | NSUN2, RNMT, NSUN3 | TK2 687/4885TK1 979/4885TOP2A 1579/4885 |
| US-10993995-B2 | Enzymatic replacement therapy and antisense therapy for pompe disease | GAA, GBA3, GBA1 | TK2 1877/4885TK1 443/4885TOP2A 4164/4885 |
| US-20220288100-A1 | 2'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS | NSUN2, SNRPE, RBM3 | TK2 2210/4885TK1 2727/4885TOP2A 3470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.